Want to see VRTX full AI Analyst Report?
Vertex Pharmaceuticals (VRTX) AI Stock Analysis
Top Page
Vertex Pharmaceuticals
(NASDAQ:VRTX)
VRTX scores well primarily due to strong financial performance (high margins, solid free cash flow, and a conservative balance sheet) and a positive earnings-call backdrop with raised 2026 guidance and launch/pipeline progress. The overall score is tempered by only neutral technical momentum and a middling valuation (P/E ~28 with no dividend yield provided), plus near-term margin/OpEx pressure and volatility risks highlighted on the call.
Vertex Pharmaceuticals Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down sales by region so you can see how reliant Vertex is on the U.S. versus Europe and other markets. Geographic concentration highlights exposure to local pricing, reimbursement, and regulatory risks, while growth outside core markets points to new patient access and diversification opportunities.
Vertex Pharmaceuticals' revenue growth is robust across all regions, with the U.S. leading due to the successful launch of ALYFTREK and strong CF franchise performance. Europe shows steady growth, supported by ALYFTREK's approval and reimbursement. The 'Other' category, while smaller, also contributes positively. The earnings call underscores this momentum, highlighting a 12% year-over-year revenue increase and successful product launches. However, challenges in the pain program and trial setbacks for VX-993 could impact future growth. Overall, Vertex's strategic focus on CF and new therapies is driving significant revenue gains.
The FlyVertex Pharmaceuticals (VRTX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $141.65B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.19M
- Price to Earnings (P/E)
- 32.3
- Beta (1Y)
- 0.43
- Revenue Growth
- 11.45%
- EPS Growth
- 22.53%
- Country
- US
- Employees
- 6,400
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Vertex Pharmaceuticals Business Overview & Revenue Model
Company Description
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for...
How the Company Makes Money
Vertex makes money primarily by selling its prescription medicines, with the bulk of revenue historically derived from its cystic fibrosis franchise. Revenue is generated when Vertex supplies its drugs to specialty pharmacies, hospitals, and distribu...
Vertex Pharmaceuticals Earnings Call Summary
The call presented a largely positive commercial and clinical update: revenue and key product launches (ALYFTREK, CASGEVY, JOURNAVX) showed strong momentum, guidance was raised, multiple clinical and regulatory milestones were achieved or on track (Pove BLA accepted, AMPLITUDE/AMPLIFIED/AGLOW enrollment complete or progressing, VX‑017 IND cleared), and the Crinetics acquisition adds a new specialty pillar. Offsetting factors include higher SG&A and upcoming operating expense at the high end of guidance, gross margin pressure from product mix and manufacturing investments, short‑term revenue volatility for cell therapies and PSP‑driven gross‑to‑net impacts (normalization expected in H1 2027), and near‑term costs and debt associated with the Crinetics deal. Overall, the positive commercial execution and pipeline progress outweigh the near‑term cost and execution risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Vertex raised full‑year 2026 revenue guidance to $13.1–$13.2 billion while reiterating expectations for at least $500 million of non‑CF revenue and a roughly 150 basis‑point net benefit from foreign exchange; full‑year gross margin is expected to be just under 86% and combined non‑GAAP operating expenses are guided to $5.65–$5.75 billion (with management expecting to be at the high end). They expect a non‑GAAP effective tax rate of 19.5%–20.5% for 2026 (YTD at 20.4%), noted that the pending Crinetics acquisition (~$8.8 billion net of cash, to be funded with cash plus a $4.5 billion term loan) is expected to close in Q3 with modest 2026 P&L impact and to be accretive to non‑GAAP operating income in 2029, and said they will update 2026 guidance at close. Quarterly metrics highlighted alongside guidance included Q2 revenue of $3.3 billion (+12% YoY, with ~170 bps FX benefit), Q2 gross margin of 85.6%, Q2 non‑GAAP EPS of $4.73 (+5% YoY), Q2 non‑GAAP R&D of $889 million and SG&A of $520 million, cash and investments of ~$13.6 billion, and Q2 share repurchases of ~$455 million (~1 million shares).
Vertex Pharmaceuticals Financial Statement Overview
Summary
Financial statements show high-quality profitability and cash generation: TTM revenue of $12.62B with very strong margins (gross ~86%, EBIT ~42%, net ~35%) and solid free cash flow ($3.80B). Balance sheet is a key strength with high equity ($20.25B) and improved leverage (TTM total debt shown at $0). Main risk is notable year-to-year lumpiness (2024 profitability and cash flow disruption) despite strong recovery in 2025 and TTM.
Income Statement
86Very PositiveBalance Sheet
88Very PositiveCash Flow
83Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.62B | 12.07B | 11.02B | 9.87B | 8.93B | 7.57B |
| Gross Profit | 10.86B | 10.27B | 9.49B | 8.61B | 7.85B | 6.67B |
| EBITDA | 5.50B | 4.87B | 486.30M | 4.61B | 4.44B | 2.92B |
| Net Income | 4.41B | 3.95B | -535.60M | 3.62B | 3.32B | 2.34B |
Balance Sheet | ||||||
| Total Assets | 27.42B | 26.14B | 22.53B | 22.73B | 18.15B | 13.43B |
| Cash, Cash Equivalents and Short-Term Investments | 7.85B | 6.61B | 6.12B | 11.22B | 10.78B | 7.52B |
| Total Debt | 1.98B | 3.88B | 1.75B | 808.40M | 899.70M | 967.40M |
| Total Liabilities | 7.18B | 7.48B | 6.12B | 5.15B | 4.24B | 3.33B |
| Stockholders Equity | 20.25B | 18.67B | 16.41B | 17.58B | 13.91B | 10.10B |
Cash Flow | ||||||
| Free Cash Flow | 3.80B | 3.19B | -790.30M | 3.28B | 3.93B | 2.41B |
| Operating Cash Flow | 4.29B | 3.63B | -492.60M | 3.54B | 4.13B | 2.64B |
| Investing Cash Flow | -882.80M | -945.40M | -3.77B | -3.14B | -321.10M | -340.90M |
| Financing Cash Flow | -2.20B | -2.26B | -1.49B | -562.20M | -67.70M | -1.48B |
Vertex Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRTX, the sentiment is Positive. The current price of 558.88 is above the 20-day moving average (MA) of 514.56, above the 50-day MA of 523.21, and above the 200-day MA of 479.21, indicating a bullish trend. The MACD of 6.61 indicates Negative momentum. The RSI at 67.65 is Neutral, neither overbought nor oversold. The STOCH value of 85.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VRTX.
Vertex Pharmaceuticals Risk Analysis
Vertex Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Vertex Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
2 New RisksVertex Pharmaceuticals Peers Comparison
Overall Rating
- VRTX75Outperform
ALNY71Outperform
BMRN61Neutral
NTLA58Neutral
SRPT58Neutral
CRSP54Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| VRTX | 75Outperform | $141.65B | 32.27 | 23.31% | ― | 11.45% | 22.53% |
| ALNY | 71Outperform | $22.10B | 8.10 | 159.72% | ― | 56.17% | 6459.20% |
| BMRN | 61Neutral | $11.33B | 153.97 | 1.18% | ― | 13.69% | -89.03% |
| NTLA | 58Neutral | $1.75B | -3.71 | -57.79% | ― | 12.58% | 28.42% |
| SRPT | 58Neutral | $1.97B | -12.93 | -9.96% | ― | -20.44% | -349.84% |
| CRSP | 54Neutral | $4.97B | -10.80 | -24.39% | ― | -64.80% | 12.20% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc. | 558.88 | 132.88 | 31.19% | |
| ALNY | Alnylam Pharmaceuticals | 165.00 | -269.07 | -61.99% | |
| BMRN | Biomarin Pharmaceutical Inc. | 58.51 | 5.66 | 10.71% | |
| SRPT | Sarepta Therapeutics Inc. | 18.62 | -5.83 | -23.84% | |
| NTLA | Intellia Therapeutics Inc | 12.47 | -0.60 | -4.59% | |
| CRSP | Crispr Therapeutics | 51.42 | -10.55 | -17.02% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 05, 2026